Cancer Letters 2017, 400:161.
CLICK HERE ➔ to full-length paper, which might require a subscription
This is the first published report on our proprietary compound NEO218, which consists of perillyl alcohol conjugated to 3-bromopyruvate (3-BP). Although 3-BP has anticancer activity of its own, some tumor cells are able to rapidly develop resistance to this agent and continue to grow despite continued drug treatment. In contrast, we show in this preclinical study that NEO218 suppresses the development of drug resistance and is effective against tumor cells derived from a variety of different tumor types. As well, NEO218 is able to kill tumor cells that otherwise are not killed by 3-BP.